Symptomatic Intracranial Hemorrhage After Stroke Thrombolysis Comparison of Prediction Scores
|
|
- Ashley Bishop
- 5 years ago
- Views:
Transcription
1 Symptomatic Intracranial Hemorrhage After Stroke Thrombolysis Comparison of Prediction Scores Daniel Strbian, MD, PhD, MSc (Stroke Med); Patrik Michel, MD; David J. Seiffge, MD; Jeffrey L. Saver, MD, FAHA; Heikki Numminen, MD, PhD; Atte Meretoja, MD, PhD, MSc (Stroke Med); Kei Murao, MD; Bruno Weder, MD; Nina Forss, MD, PhD; Anna-Kaisa Parkkila, MD, PhD; Ashraf Eskandari, RN; Charlotte Cordonnier, MD, PhD; Stephen M. Davis, MD, PhD; Stefan T. Engelter, MD, PhD; Turgut Tatlisumak, MD, PhD Background and Purpose Several prognostic scores have been developed to predict the risk of symptomatic intracranial hemorrhage (sich) after ischemic stroke thrombolysis. We compared the performance of these scores in a multicenter cohort. Methods We merged prospectively collected data of patients with consecutive ischemic stroke who received intravenous thrombolysis in 7 stroke centers. We identified and evaluated 6 scores that can provide an estimate of the risk of sich in hyperacute settings: MSS (Multicenter Stroke Survey); HAT (Hemorrhage After Thrombolysis); SEDAN (blood sugar, early infarct signs, [hyper]dense cerebral artery sign, age, NIH Stroke Scale); GRASPS (glucose at presentation, race [Asian], age, sex [male], systolic blood pressure at presentation, and severity of stroke at presentation [NIH Stroke Scale]); SITS (Safe Implementation of Thrombolysis in Stroke); and SPAN (stroke prognostication using age and NIH Stroke Scale)-100 positive index. We included only patients with available variables for all scores. We calculated the area under the receiver operating characteristic curve (AUC-ROC) and also performed logistic regression and the Hosmer Lemeshow test. Results The final cohort comprised 3012 eligible patients, of whom 221 (7.3%) had sich per National Institute of Neurological Disorders and Stroke, 141 (4.7%) per European Cooperative Acute Stroke Study II, and 86 (2.9%) per Safe Implementation of Thrombolysis in Stroke criteria. The performance of the scores assessed with AUC-ROC for predicting European Cooperative Acute Stroke Study II sich was: MSS, 0.63 (95% confidence interval, ); HAT, 0.65 ( ); SEDAN, 0.70 ( ); GRASPS, 0.67 ( ); SITS, 0.64 ( ); and SPAN-100 positive index, 0.56 ( ). SEDAN had significantly higher AUC-ROC values compared with all other scores, except for GRASPS where the difference was nonsignificant. SPAN-100 performed significantly worse compared with other scores. The discriminative ranking of the scores was the same for the National Institute of Neurological Disorders and Stroke, and Safe Implementation of Thrombolysis in Stroke definitions, with SEDAN performing best, GRASPS second, and SPAN-100 worst. Conclusions SPAN-100 had the worst predictive power, and SEDAN constantly the highest predictive power. However, none of the scores had better than moderate performance. (Stroke. 2014;45: ) The only approved clot-busting medical treatment in ischemic stroke, intravenous thrombolysis (IVT), is not without complications. One of the major reasons for withholding the therapy remains fear of symptomatic intracranial hemorrhage (sich), which can worsen patients outcomes. 1 The number needed for IVT to cause fatal sich is 36.5, and to cause any Key Word: intracranial hemorrhages worsening of outcome ( 1 grade on modified Rankin Scale) ranges from 29.7 to There are several scoring systems for predicting the risk of sich. 3 8 In an ideal situation, a prediction score could identify patients with very high risk of postthrombolysis sich. We aimed to compare the performance of existing risk prediction scores in a large multicenter cohort. Received October 9, 2013; final revision received December 4, 2013; accepted December 17, From the Departments of Neurology and Stroke Units, Helsinki University Central Hospital, Helsinki, Finland (D.S., A.M., N.F., T.T.); Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland (P.M., A.E.); University Hospital Basel, Basel, Switzerland (D.J.S., S.T.E.); Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA (J.L.S.); Tampere University Hospital, Tampere, Finland (H.N., A.-K.P.); The Royal Melbourne Hospital, Parkville, Australia (A.M., S.M.D.); University Lille Nord de France, Lille, France (K.M., C.C.); and Kantonsspital St Gallen, St Gallen, Switzerland (B.W.). Guest Editor for this article was Tatjana Rundek, MD, PhD. The online-only Data Supplement is available with this article at /-/DC1. Correspondence to Daniel Strbian, MD, PhD, Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 4, Helsinki, Finland. daniel.strbian@hus.fi 2014 American Heart Association, Inc. Stroke is available at DOI: /STROKEAHA
2 Strbian et al Post-Thrombolytic Hemorrhage Prediction Scores 753 Table 1. Score/Derivation Cohort MSS (NINDS sich): derivation cohort, n=481; validation, n=965 HAT (NINDS sich): derivation, n=302; validation, n=98 SEDAN (ECASS-II sich): derivation, n=974; validation, n=828 GRASPS (NINDS sich): derivation, n=7169; validation, n=3073 SITS (SITS sich): derivation, n=15 814; validation, n= SPAN-100 (NINDS sich): no derivation; validation, n=312 Description of the Scores Parameters in the Score Cut-Off Values, Score Points, pt Age, y >60 y, 1 pt NIHSS score >10, 1 pt Blood glucose, mmol/l >8.325, 1 pt Platelet count/mm 3 < , 1 pt NIHSS score 15 20, 1 pt; >20, 2 pt Blood glucose or DM >200 mg/dl or DM, 1 pt Hypodensity on CT <1, 1 pt; 1, 2 pt (middle cerebral artery thirds) Age, y >75, 1 pt NIHSS score 10, 1 pt Blood glucose, mmol/l , 1 pt; >12.0, 2 pt Early infarct signs Yes, 1 pt Hyperdense artery signs Yes, 1 pt Age, y 60, 8 pt; 61 70, 11 pt; 71 80, 15 pt; >80, 17 pt NIHSS score 0 5, 25 pt; 6 10, 27 pt; 11 15, 34 pt; 16 20, 40 pt; >20, 42 pt Blood glucose, mg/dl <100, 2 pt; , 6 pt; 150, 8 pt Systolic blood pressure, mm Hg Ethnicity Sex Age, y NIHSS score Blood glucose, mg/dl Aspirin/clopidogrel Systolic blood pressure, mm Hg Weight, kg Onset-to-treatment time, min History of hypertension Sum of age (y) and NIHSS (score) <120, 10 pt; , 14 pt; , 18 pt; 180, 21 pt Asian, 9 pt Men, 4 pt 72, 1 pt 7 12, 1 pt; 13, 2 pt 180, 2 pt Aspirin only, 2 pt; aspirin plus clopidogrel, 3 pt 146, 1 pt 95, 1 pt 180, 1 pt Yes, 1 pt 100, positive index Name of the score is followed by criteria of symptomatic intracranial hemorrhage (sich) in the derivation. DM indicates diabetes mellitus; ECASS-II, European Cooperative Acute Stroke Study II; GRASPS, glucose at presentation, race (Asian), age, sex (male), systolic blood pressure at presentation, and severity of stroke at presentation (NIH Stroke Scale); HAT, Hemorrhage After Thrombolysis; MSS, Multicenter Stroke Survey; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; SEDAN, blood sugar, early infarct signs, (hyper)dense cerebral artery sign, age, NIH Stroke Scale; SITS, Safe Implementation of Thrombolysis in Stroke; and SPAN, stroke prognostication using age and NIH Stroke Scale. Patients and Methods Study Setting The current analysis comprises data from 7 centers. The study was approved by the relevant authorities in each participating center per local requirements. This study was approved in the coordinating center (Helsinki) as a quality registry and did not require review by the ethical board. All patients were prospectively included in the database. Data from individual consecutive patients receiving IVT within a 4.5- hour time window for acute ischemic stroke were collected using a standardized form with predefined variables. For sich definitions, radiological ICH categorization (hemorrhagic infarction 1 and 2, parenchymal hemorrhage 1 and 2) was collected and used to prospectively assign sich for the current study by 1 of the study authors in a blinded fashion. Data from all the centers were compiled in the coordinating center, where the analyses of pooled data were performed. The baseline population comprised 3543 patients. We excluded 531 patients lacking data necessary to calculate 1 of the scores; hence, the final cohort included 3012 patients with ischemic stroke in anterior or posterior circulation. None of the patients underwent endovascular procedure. None of the patients in the current analysis was included in the derivation cohort of any of the scores/indices. Selection Criteria for sich Risk Scores First, we only considered scores and indices but not regression models, because our aim was to evaluate only tools that are suitable for quick bedside calculations without depending on potentially time-consuming, computer-based systems. Second, we considered only scores and indices based on parameters available shortly after admission, before Table 2. Demographics, Baseline Characteristics, and Frequencies of Symptomatic Intracranial Hemorrhage Parameters n=3012 Age, y 71 (60 79) Women 1287 (42.7%) Weight, kg 78 (68 90) Onset-to-treatment time, min 145 ( ) Baseline NIHSS score, points 10 (6 17) Hyperdense cerebral artery signs 759 (25.2%) Early infarct signs 864 (28.7%) Prestroke mrs >1 153 (5.1%) Prethrombolysis BP and glucose level Systolic BP, mm Hg 156 ( ) Diastolic BP, mm Hg 84 (74 94) Platelets/mm ( ) Glucose, mmol/l 6.7 ( ) Medical history and medication Hypertension 1923 (63.8%) Diabetes mellitus 533 (17.7%) Aspirin 1046 (34.7%) Aspirin or clopidogrel 63 (2.1%) Frequencies of symptomatic intracranial hemorrhage ECASS-II criteria 141 (4.7%) NINDS criteria 221 (7.3%) SITS criteria 86 (2.9%) Data are presented as median (interquartile range) or percentage. BP indicates blood pressure; ECASS-II, European Cooperative Acute Stroke Study II; mrs, modified Rankin Scale; NIHSS, National Institites of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; and SITS, Safe Implementation of Thrombolysis in Stroke.
3 754 Stroke March 2014 administration of thrombolysis. Finally, we included scores that had been primarily developed to predict another outcome, such as final disability level, if they also had been previously tested and shown to predict risk of symptomatic hemorrhage after IVT. Statistical Analyses We tested the ability of the scores/indices to predict the risk of post-thrombolytic sich according to the criteria of European Cooperative Acute Stroke Study II (ECASS-II) trial, National Institute of Neurological Disorders and Stroke (NINDS) study, and Safe Implementation of Thrombolysis in Stroke (SITS) registry Discrimination was judged with c-statistics and area under the receiver operating characteristic curve (AUC-ROC). Logistic regression determined the odds ratios for all sich criteria per point increase of the scores. Calibration was assessed with the Hosmer Lemeshow test, which is a quality control statistical test for goodness of fit for the logistic regression model. It has been frequently used to test the calibration of risk prediction models. This test assesses whether or not the observed event rates matched the expected rates in subgroups of the model population. When the expected and observed event rates are similar (hence the P value for the Hosmer Lemeshow test is high), the models are considered well calibrated. The analyses were performed on IBM SPSS 21 (IBM Corp, Armonk, NY), SigmaPlot 11.0 (Systat Software, Inc, Chicago, IL), and Confidence Interval Analysis (version 2.1.2; Trevor Bryant, University of Southampton). A 2-tailed P value <0.05 was considered statistically significant. Results We identified 6 scores/indices that fulfilled our selection criteria: MSS (published in 2008), 3 HAT (2008), 4 SEDAN (2012), 5 GRASPS (2012), 6 SITS (2012), 7 and SPAN-100 positive index (2013) 8 (Table 1). The merged cohort (n=3012) is described in Table 2. The excluded patients (15%) did not differ from the included patients in demographics and baseline characteristics (data not shown). The numbers of included patients per center were: Basel, Switzerland (n=680); Helsinki, Finland (n=452); Lausanne, Switzerland (n=540); Lille, France (n=273); Melbourne, Australia (n=322); St Gallen, Switzerland (n=156), and Tampere, Finland (n=589). In the whole data set, we observed 141 (4.7%; 95% confidence interval [CI], ) cases of sich according to ECASS-II criteria, 221 (7.3%; 95% CI, ) cases according to NINDS criteria, and 86 (2.9%; 95% CI, ) cases according to SITS criteria. Center-specific frequencies of sich ranged from 3.1% to Figure 1. Frequencies of symptomatic intracranial hemorrhage according to the criteria of National Institute of Neurological Disorders and Stroke for each point level of the predictive scores. Number in parentheses represents patients who reached that specific score points. Because of the complexity of GRASPS, not all n for particular score points are shown. GRASPS indicates glucose at presentation, race (Asian), age, sex (male), systolic blood pressure at presentation, and severity of stroke at presentation (NIH Stroke Scale); HAT, Hemorrhage After Thrombolysis; MSS, Multicenter Stroke Survey; SEDAN, blood sugar, early infarct signs, (hyper)dense cerebral artery sign, age, NIH Stroke Scale; SITS, Safe Implementation of Thrombolysis in Stroke; and SPAN, stroke prognostication using age and NIH Stroke Scale.
4 Strbian et al Post-Thrombolytic Hemorrhage Prediction Scores 755 Figure 2. Frequencies of symptomatic intracranial hemorrhage according to the criteria of European Cooperative Acute Stroke Study II for each point level of the predictive scores. Number in parentheses represents patients who reached that specific score points. Because of the complexity of GRASPS, not all n for particular score points are shown. GRASPS indicates glucose at presentation, race (Asian), age, sex (male), systolic blood pressure at presentation, and severity of stroke at presentation (NIH Stroke Scale); HAT, Hemorrhage After Thrombolysis; MSS, Multicenter Stroke Survey; SEDAN, blood sugar, early infarct signs, (hyper)dense cerebral artery sign, age, NIH Stroke Scale; SITS, Safe Implementation of Thrombolysis in Stroke; and SPAN, stroke prognostication using age and NIH Stroke Scale. 9.3% (ECASS-II criteria), from 4.4% to 9.9% (NINDS), and from 2.2% to 5.1% (SITS). Frequencies of sich, according to the 3 criteria, 1 per point increase of the scores are outlined in Figures 1 3 and Figure I in the online-only Data Supplement. Based on the logistic regression analysis, all scores were associated with sich according to all 3 criteria (Table I in the online-only Data Supplement). The results of the Hosmer Lemeshow test showed worst model fit for GRASPS in case of ECASS-II sich. Because SPAN-100 is a binary index, the test could not have been calculated. Score comparisons by means of AUC-ROCs are presented separately for each sich definition (Table 3). SEDAN had the highest absolute values of AUC-ROC in all analyses, and except for the comparison with GRASPS, these differences were statistically significant. SPAN-100 positive index had the lowest AUC-ROC values in all comparisons. Discussion With comprehensive data from several dedicated stroke centers, we had a unique opportunity to perform a head-to-head comparison of the existing sich prediction scores. In general, SPAN- 100 showed poor predictive power, and all other scores moderate predictive power. Of all scores, SEDAN had constantly the highest nominal predictive performance in all comparisons, most of which were statistically significant, except for the comparison with GRASPS, which showed the second highest AUC- ROC values. In 2-way comparisons, the differences between GRASPS and other scores were frequently nonsignificant. We observed rather low frequencies of post-thrombolytic sich in the current merged cohort with considerable intercenter differences. This contributes to the relatively low risk of sich even with the worst scores compared with the original reports (perhaps with the exception of MSS and HAT, relatively smaller number of patients scored the highest points). Nonetheless, what is crucial is that the relative risk of high-risk patients compared with low-risk patients remained similar. For example, according to the original report, 5 a patient with SEDAN of 5 had almost 4-fold higher risk of sich (33.3%) compared with SEDAN of 2 (8.5%) and >20-fold higher risk compared with SEDAN of 0 (1.4%). Here, the magnitude of these relative risks remained similar, 4 and 18, respectively. Taken together, the scores consist of parameters related to (1) underlying parenchymal injury, microangiopathy (age, history of hypertension and diabetes mellitus, blood glucose as a marker of diabetes mellitus history), (2) degree of acute parenchymal injury (CT findings and, to certain level, also the
5 756 Stroke March 2014 Figure 3. Frequencies of symptomatic intracranial hemorrhage according to the criteria of Safe Implementation of Thrombolysis in Stroke for each point level of the predictive scores. Number in parentheses represents patients who reached that specific score points. Because of the complexity of GRASPS, not all n for particular score points are shown. GRASPS indicates glucose at presentation, race (Asian), age, sex (male), systolic blood pressure at presentation, and severity of stroke at presentation (NIH Stroke Scale); HAT, Hemorrhage After Thrombolysis; MSS, Multicenter Stroke Survey; SEDAN, blood sugar, early infarct signs, (hyper)dense cerebral artery sign, age, NIH Stroke Scale; SITS, Safe Implementation of Thrombolysis in Stroke; and SPAN, stroke prognostication using age and NIH Stroke Scale. National Institutes of Health Stroke Scale [NIHSS] and onsetto-treatment time), (3) coagulation process (platelet count, use of antiplatelet agents, and perhaps patient s weight determining the dose of alteplase), (4) physical factors (systolic blood pressure), and (5) sex and ethnicity. In fact, modest differences in the AUC-ROC values among the scores reflect that most of the scores include similar components: age, NIHSS, and baseline glucose level being the most common (Tables 1 and 3). The differences are often in the relative weighting given to individual components. SPAN-100 (consisting of age and NIHSS) had rather low AUC-ROC values according to all sich criteria ( ) as compared with 0.73 per NINDS criteria in the original report. 8 Potential explanations may be that SPAN-100 was postulated rather than derived from a specific cohort. Also, validation was performed in a rather small cohort of 312 patients with IVT from the NINDS trial. Furthermore, the timing of treatment in the present study was, on average, somewhat later than in the NINDS patients, half of whom were treated <90 minutes and all <3 hours of symptom onset. Although patient s age and baseline stroke severity are major components of all the scores, our data showed that other parameters also matter. Imaging parameters (necessary for the calculation of HAT and SEDAN) seem to improve the performance of outcome prediction scores. 12 Although their assessing requires training, we think it is readily achievable with continuous education in centers delivering IVT. Interestingly, platelet count was included in 1 score only (MSS), but it did not, for example, improve the model of SEDAN (data not shown). One possible explanation is the fact that a vast majority of patients in its derivation cohort had similar platelet counts, being in the physiological range. Another source of differences in the performances of scores may reflect the fact that they were derived to predict particular definitions of sich. For example, SITS had higher AUC-ROC values than for ECASS-II or NINDS criteria (Table 3). SEDAN had the highest AUC-ROC value for sich per ECASS-II definition, for which it was developed. Whereas, GRASPS had almost identical AUC-ROC values for each definition. Another aspect influencing the performance of scores is the number of component items. Scores derived from larger data sets, such as GRASPS and SITS, had the statistical power to detect the significance for more parameters, but also made the scores somewhat complex (in case of GRASPS requiring computer-based platforms). Potential points in GRASPS
6 Strbian et al Post-Thrombolytic Hemorrhage Prediction Scores 757 Table 3. Areas Under the Curves (AUC) and P Values for Their Comparisons MSS HAT SEDAN GRASPS SITS SPAN-100 sich NINDS study AUC (95% CI) 0.62 ( ) 0.65 ( ) 0.69 ( ) 0.67 ( ) 0.61 ( ) 0.55 ( ) MSS 0.10 <0.001 < HAT <0.001 SEDAN < <0.001 <0.001 GRASPS < <0.01 <0.001 SITS <0.001 < SPAN <0.001 <0.001 < sich ECASS-II trial AUC (95% CI) 0.63 ( ) 0.65 ( ) 0.70 ( ) 0.67 ( ) 0.64 ( ) 0.56 ( ) MSS HAT SEDAN <0.001 GRASPS <0.01 SITS SPAN <0.001 < sich SITS registry AUC (95% CI) 0.66 ( ) 0.64 ( ) 0.69 ( ) 0.67 ( ) 0.67 ( ) 0.56 ( ) MSS HAT SEDAN <0.01 GRASPS SITS SPAN < ECASS-II indicates European Cooperative Acute Stroke Study II; GRASPS, glucose at presentation, race (Asian), age, sex (male), systolic blood pressure at presentation, and severity of stroke at presentation (NIH Stroke Scale); HAT, Hemorrhage After Thrombolysis; MSS, Multicenter Stroke Survey; NIHSS, National Institutes of Health Stroke Scale; SEDAN, blood sugar, early infarct signs, (hyper)dense cerebral artery sign, age, NIH Stroke Scale; sich, symptomatic intracranial hemorrhage; SITS, Safe Implementation of Thrombolysis in Stroke; and SPAN, stroke prognostication using age and NIH Stroke Scale. range from 45 to 101, which is most probably also the reason for considerable oscillations in sich frequencies per increasing score point (Figures 1 3 and Figure I in the online-only Data Supplement). Also, MSS and GRASPS were derived from cohorts with 3-hour time window, whereas SEDAN and SITS were derived from cohorts with 4.5-hour time window. SPAN-100 was not derived from any cohort, and HAT was based on literature search of sich predictors in studies including patients with 3-hour and 6-hour time window. All of these factors could have influenced the results. We did not include the iscore (derived for socioeconomical purposes to help with discharge planning, and in comparing facilities by policymakers) 13 in our analysis because we aimed to compare only the scores that can be applied shortly after patient s admission, before IVT. The authors of iscore acknowledged that it may take several hours to obtain all the necessary parameters to calculate the score. Indeed, it is unlikely that cause, 1 of the components of the iscore, would be ascertained within a short time frame after admission. Sung et al 14 recently compared sich scores. However, that study was rather small (n=548) and excluded SEDAN because of unavailability of imaging data in their database. In that study, the observed odds ratios based on regression models and AUC-ROC values were similar to those in our study. Moreover, the most important findings of that study (SPAN-100 had the worst predictive value, and HAT and MSS had better performance than in the original validation cohort) 15 were in line with our observations. The only difference was the worse performance by GRASPS in Sung et al s study. 14 This was perhaps because of including exclusively patients of Asian race, which was identified as a strong predictor of sich in the GRASPS model. Last but not least, the dose of tissue plasminogen activator ranged from 0.6 to 0.9 mg/kg according to the Taiwan guidelines. Another study validated SEDAN in a large data set of SITS cohort. 16 The authors of that study acknowledged some intercohort differences in baseline characteristics and a relatively large proportion (20%) of patients with unavailable parameters to calculate the score. Also, the proportion of sich per ECASS-II definition was lower in the SITS cohort (5.1%), similar to the figures from the current merged cohort but lower than that reported in the original SEDAN cohort (7.0%). Central imaging read would be probably of importance. With >750 SITS centers, it could play a role but is also challenging from a logistics and financial point of view. Furthermore, our study provides a head-to-head comparison of all existing scores. One limitation of the current study is that the database comprises almost exclusively white patients. Fifteen percent of the patients were excluded because they had parameters lacking
7 758 Stroke March 2014 for 1 of the scores, but they did not differ from the included patients in demographics and baseline characteristics. Each center performed its imaging read. However, our study represents a large sample size with patients from several centers operating under different conditions. Unfortunately, we could not analyze the scores separately in men and women or in patients treated <180 minutes and between 180 and 270 minutes because sex and treatment delays are components of some of the scores. SEDAN and SITS are the only scores that were derived and validated in patients treated in an extended thrombolysis time window of 4.5 hours. Although SEDAN had consistently the highest absolute AUC-ROC values in all analyses, the performance was only moderate. This was also the case for all other scores except for the poor performance of SPAN-100. At the moment, we must acknowledge the limitations of post-thrombolysis hemorrhage prediction scores, and we do not have the data to support withdrawal of thrombolysis treatment, which has a proven benefit, in patients with high risk of sich. We think that in future sich prediction scores may play a role in personalized and tailored medicine and can optionally be used together with the scores predicting functional outcome after IVT. 17 Patients at very high risk of sich would most probably benefit from intensive monitoring (including blood pressure and blood glucose) and alertness of the staff after IVT administration. Although not currently evidence-based, some centers may perhaps prefer refraining from IVT and proceed directly to intra-arterial procedures in patients with high likelihood of poor outcome superimposed by a high risk of sich after IVT. Another possible use of the scores would be in the selection of patients for randomized trials on add-on therapy to reduce post-thrombolytic sich. Naturally, the use of such scores can only be one part of the decision-making process, complementary to clinical, laboratory, and radiological findings. Nonetheless, we are only taking the initial steps in this area, and prediction scores will gain critical additional power and high precision over time. CT imaging may gradually be replaced by MRI; early biomarkers with quick bedside laboratory methodology may become available; and genetic profiles of individuals will probably disclose their genetic predispositions to hemorrhage. A sophisticated prediction score may probably include more detailed items, but yet the actual scores should allow quick calculations. Sources of Funding This study was supported by the Helsinki University Central Hospital (HUCH) governmental subsidiary (EVO) funds for clinical research. The authors received funding from the HUCH (D.S., A.M., T.T.), the Biomedicum Helsinki Foundation (A.M.), the Sigrid Juselius Foundation (A.M., T.T.), the Finnish Medical Foundation (A.M.), the Stroke-[Hirnschlag]-Fund Basel (D.J.S.), the Swiss National Science Foundation No. 33CM (S.T.E.), and Australian National Health and Medical Research Council Centre for Research Excellence grant (A.M., S.M.D.). The supporting sources had no involvement in the design, analyses, or interpretation of the study. Disclosures Dr Michel received research grants from the Swiss Cardiology Foundation (significant) and Cardiomet CHUV (significant), speaker fees from Boehringer-Ingelheim (modest), and advisory board compensation from Boehringer-Ingelheim (modest). Dr Davis received travel grants from EVER Neuropharma (modest) and Sanofi (modest), as well as speakers fees from Boehringer-Ingelheim (modest). Dr Tatlisumak received honoraria from Boehringer-Ingelheim (modest) and advisory board compensations from Boehringer-Ingelheim (modest) and H Lundbeck A/S (modest). The other authors have no conflicts to report. References 1. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al; Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77: Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38: Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17: Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71: Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71: Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43: Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43: Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology. 2013;80: The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333: Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352: Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369: Turc G, Apoil M, Naggara O, Calvet D, Lamy C, Tataru AM, et al. Magnetic Resonance Imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke. Stroke. 2013;44: Saposnik G, Kapral MK, Liu Y, Hall R, O Donnell M, Raptis S, et al; Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. 2011;123: Sung SF, Chen SC, Lin HJ, Chen YW, Tseng MC, Chen CH. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2013;44: Cucchiara B, Kasner S, Tanne D, Levine S, Demchuk A, Messe S, et al; SAINT Investigators. Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage. Int J Stroke. 2011;6: Mazya MV, Bovi P, Castillo J, Jatuzis D, Kobayashi A, Wahlgren N, et al. External validation of the SEDAN score for prediction of intracerebral hemorrhage in stroke thrombolysis. Stroke. 2013;44: Strbian D, Meretoja A, Ahlhelm FJ, Pitkäniemi J, Lyrer P, Kaste M, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78:
Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator
Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator Bijoy K. Menon, MD; Jeffrey L. Saver, MD; Shyam Prabhakaran, MD,
More informationMohamed Al-Khaled, MD,* Christine Matthis, MD, and J urgen Eggers, MD*
Predictors of In-hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Mohamed Al-Khaled,
More informationRe-evaluation of the stroke prognostication using age and NIH Stroke Scale index (SPAN-100 index) in IVT patients the-span index
Möbius et al. BMC Neurology (2018) 18:129 https://doi.org/10.1186/s12883-018-1126-0 RESEARCH ARTICLE Re-evaluation of the stroke prognostication using age and NIH Stroke Scale index (SPAN-100 index) in
More informationOne of the most important issues a clinician must consider
Defining Clinically Relevant Cerebral Hemorrhage After Thrombolytic Therapy for Stroke Analysis of the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Trials Neal
More informationRelationship Between Onset-to-Door Time and Door-to-Thrombolysis Time A Pooled Analysis of 10 Dedicated Stroke Centers
Relationship Between Onset-to-Door Time and Door-to-Thrombolysis Time A Pooled Analysis of 10 Dedicated Stroke Centers Daniel Strbian, MD, PhD; Patrik Michel, MD; Peter Ringleb, MD, PhD; Heikki Numminen,
More informationRole of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke
Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke Michal Karlinski, MD, PhD; Adam Kobayashi, MD, PhD; Anna Czlonkowska, MD, PhD; Robert Mikulik, MD, PhD;
More informationENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist
ENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist Pharmacy Grand Rounds 26 July 2016 2015 MFMER slide-1 Learning
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationAcute ischemic stroke is a major cause of morbidity
Outcomes of Treatment with Recombinant Tissue Plasminogen Activator in Patients Age 80 Years and Older Presenting with Acute Ischemic Stroke Jennifer C. Drost, DO, MPH, and Susana M. Bowling, MD ABSTRACT
More informationOutcome by Stroke Etiology in Patients Receiving Thrombolytic Treatment Descriptive Subtype Analysis
Outcome by Stroke Etiology in Patients Receiving Thrombolytic Treatment Descriptive Subtype Analysis Satu Mustanoja, MD, PhD; Atte Meretoja, MD, MSc; Jukka Putaala, MD, PhD; Varpu Viitanen, MB; Sami Curtze,
More informationOutcome by Stroke Etiology in Patients Receiving Thrombolytic Treatment Descriptive Subtype Analysis
Outcome by Stroke Etiology in Patients Receiving Thrombolytic Treatment Descriptive Subtype Analysis Satu Mustanoja, MD, PhD; Atte Meretoja, MD, MSc; Jukka Putaala, MD, PhD; Varpu Viitanen, MB; Sami Curtze,
More informationTissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes
Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes Demetrios J. Sahlas, MSc, MD,* Linda Gould, RPN, Richard H. Swartz, MD, PhD, Naufal Mohammed,
More informationAcute Stroke Care: the Nuts and Bolts of it. ECASS I and II ATLANTIS. Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center
Acute Stroke Care: the Nuts and Bolts of it Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center ECASS I and II tpa for patients presenting
More informationBlood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke
www.jneurology.com Neuromedicine www.jneurology.com Research Article Open Access Blood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke Hanna
More informationClinical Study Experiences of Thrombolytic Therapy for Ischemic Stroke in Tuzla Canton, Bosnia and Herzegovina
ISRN Stroke, Article ID 313976, 4 pages http://dx.doi.org/10.1155/2014/313976 Clinical Study Experiences of Thrombolytic Therapy for Ischemic Stroke in Tuzla Canton, Bosnia and Herzegovina DDevdet SmajloviT,DenisaSalihoviT,
More informationCerebral Computed Tomography-Graded White Matter Lesions Are Associated With Worse Outcome After Thrombolysis in Patients With Stroke
Cerebral Computed Tomography-Graded White Matter Lesions Are Associated With Worse Outcome After Thrombolysis in Patients With Stroke Sami Curtze, MD, PhD; Susanna Melkas, MD, PhD; Gerli Sibolt, MD; Elena
More informationSetting The setting was secondary care. The economic analysis was conducted in Vancouver, Canada.
Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke Sinclair S E, Frighetto, Loewen P S, Sunderji R, Teal P, Fagan S C, Marra C A Record Status This is a critical abstract
More informationTreatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke A Scientific Statement for Healthcare Professionals from the American Heart Association/American
More informationMicrobleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients With Acute Ischemic Stroke
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients With Acute Ischemic Stroke Guillaume Turc, MD; Asmaa Sallem, MD; Solène Moulin, MD; Marie Tisserand, MD; Alexandre Machet,
More informationEndovascular Treatment for Acute Ischemic Stroke
ular Treatment for Acute Ischemic Stroke Vishal B. Jani MD Assistant Professor Interventional Neurology, Division of Department of Neurology. Creighton University/ CHI health Omaha NE Disclosure None 1
More informationAn Updated Systematic Review of rt-pa in Acute Ischaemic Stroke
Wardlaw An Updated Systematic Review of rt-pa in Acute Ischaemic Stroke Joanna M Wardlaw COMPETING INTERESTS The author is on the Steering Committees of the Third International Stroke Trial (IST3) and
More informationThe tpa Cage Match. Disclosures. Cage Match. Cage Match 1/27/2014. January 8, Advisory Boards
The tpa Cage Match January 8, 2014 Andy Jagoda, MD, FACEP Professor and Chair of Emergency Medicine Mount Sinai School of Medicine New York, New York Advisory Boards Disclosures Astra Zeneca, Pfizer, CSL
More informationEmergency Department Management of Acute Ischemic Stroke
Emergency Department Management of Acute Ischemic Stroke R. Jason Thurman, MD Associate Professor of Emergency Medicine and Neurosurgery Associate Director, Vanderbilt Stroke Center Vanderbilt University,
More informationMechanical thrombectomy in Plymouth. Will Adams. Will Adams
Mechanical thrombectomy in Plymouth Will Adams Will Adams History Intra-arterial intervention 1995 (NINDS) iv tpa improved clinical outcome in patients treated within 3 hours of ictus but limited recanalisation
More informationSafety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke
Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke Etsuro Mori, MD, PhD; Kazuo Minematsu, MD, PhD; Jyoji Nakagawara, MD, PhD; Yasuhiro
More informationPARADIGM SHIFT FOR THROMBOLYSIS IN PATIENTS WITH ACUTE ISCHAEMIC STROKE, FROM EXTENSION OF THE TIME WINDOW TO RAPID RECANALISATION AFTER SYMPTOM ONSET
PARADIGM SHIFT FOR THROMBOLYSIS IN PATIENTS WITH ACUTE ISCHAEMIC STROKE, FROM EXTENSION OF THE TIME WINDOW TO RAPID RECANALISATION AFTER SYMPTOM ONSET Hye Seon Jeong, *Jei Kim Department of Neurology and
More informationRole of recombinant tissue plasminogen activator in the updated stroke approach
Role of recombinant tissue plasminogen activator in the updated stroke approach Joshua Z. Willey, MD, MS Assistant Professor of Neurology Division of Stroke, Columbia University October 2015 jzw2@columbia.edu
More information11/27/2017. Stroke Management in the Neurocritical Care Unit. Conflict of interest. Karel Fuentes MD Medical Director of Neurocritical Care
Stroke Management in the Neurocritical Care Unit Karel Fuentes MD Medical Director of Neurocritical Care Conflict of interest None Introduction Reperfusion therapy remains the mainstay in the treatment
More informationBritish Geriatrics Society
Healthcare professional group/clinical specialist statement Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationOutcomes of intravenous thrombolysis in posterior versus anterior circulation stroke
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse CH-0 Zurich www.zora.uzh.ch Year: 0 Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke
More informationAcute Stroke Treatment: Current Trends 2010
Acute Stroke Treatment: Current Trends 2010 Helmi L. Lutsep, MD Oregon Stroke Center Oregon Health & Science University Overview Ischemic Stroke Neuroprotectant trials to watch for IV tpa longer treatment
More informationStroke Update. Lacunar 19% Thromboembolic 6% SAH 13% ICH 13% Unknown 32% Hemorrhagic 26% Ischemic 71% Other 3% Cardioembolic 14%
Stroke Update Michel Torbey, MD, MPH, FAHA, FNCS Medical Director, Neurovascular Stroke Center Professor Department of Neurology and Neurosurgery The Ohio State University Wexner Medical Center Objectives
More informationDoor to Needle Time: Gold Standard of Stroke Treatment Fatima Milfred, MD. Virginia Mason Medical Center March 16, 2018
Door to Needle Time: Gold Standard of Stroke Treatment Fatima Milfred, MD Virginia Mason Medical Center March 16, 2018 2016 Virginia Mason Medical Center No disclosure 2016 Virginia Mason Medical Center
More informationTranslent CT hyperattenuation after intraarterial thrombolysis in stroke. Contrast extravasation or hemorrhage
Translent CT hyperattenuation after intraarterial thrombolysis in stroke. Contrast extravasation or hemorrhage Poster No.: C-0053 Congress: ECR 2013 Type: Scientific Exhibit Authors: A. Losa Palacios,
More informationPrediction of Poststroke Hemorrhagic Transformation Using Computed Tomography Perfusion
Prediction of Poststroke Hemorrhagic Transformation Using Computed Tomography Perfusion Nawaf Yassi, MBBS, BSc (Med), FRACP; Mark W. Parsons, PhD, FRACP; Søren Christensen, PhD; Gagan Sharma, MCA; Andrew
More informationIschemic stroke is one of the most common causes of death
Stroke Lesion Volumes and Outcome Are Not Different in Hemispheric Stroke Side Treated With Intravenous Thrombolysis Based on Magnetic Resonance Imaging Criteria Amir Golsari, MD; Bastian Cheng, MD; Jan
More informationUpdated tpa Guidelines: Expanding the opportunity for good outcomes. Benjamin Morrow, MSN RN UPMC Stroke Institute
Updated tpa Guidelines: Expanding the opportunity for good outcomes Benjamin Morrow, MSN RN UPMC Stroke Institute 1 Outline History Current State Review Exclusions: Minor stroke symptoms Severe strokes
More informationSubtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator Mervyn D.I. Vergouwen, MD, PhD; Leanne K. Casaubon, MD, MSc; Richard
More informationNeurological Deterioration in Acute Ischemic Stroke
Neurological Deterioration in Acute Ischemic Stroke Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) I A. Dávalos, MD; D. Toni, MD; F. Iweins, MSc; E.
More informationJointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Genentech, A Member of the Roche Group
Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Genentech, A Member of the Roche Group Faculty Speakers Deepak L. Bhatt, MD, MPH, FACC, FAHA,
More informationSafety and Efficacy of Thrombolysis in Cervical Artery Dissection-Related Ischemic Stroke: A Meta-Analysis of Observational Studies
Review Received: September 29, 2015 Accepted: April 6, 2016 Published online: May 21, 2016 Safety and Efficacy of Thrombolysis in Cervical Artery Dissection-Related Ischemic Stroke: A Meta-Analysis of
More informationThe Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment
The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Adnan I. Qureshi, MD 1, Muhammad A. Saleem, MD 1, Emrah Aytaç, MD
More informationUpdated Ischemic Stroke Guidelines นพ.ส ชาต หาญไชยพ บ ลย ก ล นายแพทย ทรงค ณว ฒ สาขาประสาทว ทยา สถาบ นประสาทว ทยา กรมการแพทย กระทรวงสาธารณส ข
Updated Ischemic Stroke Guidelines นพ.ส ชาต หาญไชยพ บ ลย ก ล นายแพทย ทรงค ณว ฒ สาขาประสาทว ทยา สถาบ นประสาทว ทยา กรมการแพทย กระทรวงสาธารณส ข Emergency start at community level: Prehospital care Acute stroke
More informationDetection of neurological symptoms of stroke on awakening
Treating Patients With Wake-Up Stroke The Experience of the AbESTT-II Trial Harold P. Adams, Jr, MD; Enrique C. Leira, MD; James C. Torner, PhD; Elliot Barnathan, MD; Lakshmi Padgett, PhD; Mark B. Effron,
More informationWhen Not To Give TPA Steve Phillips Division of Neurology
When Not To Give TPA Steve Phillips Division of Neurology stephen.phillips@nshealth.ca AstraZeneca Disclosures - 1 I have given CME lectures and served on advisory boards for Boehringer Ingelheim Bristol-Myers
More informationEarly neurological worsening in acute ischaemic stroke patients
Acta Neurol Scand 2016: 133: 25 29 DOI: 10.1111/ane.12418 2015 The Authors. Acta Neurologica Scandinavica Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Early neurological in acute ischaemic
More informationACUTE STROKE TREATMENT IN LARGE NIHSS PATIENTS. Justin Nolte, MD Assistant Profession Marshall University School of Medicine
ACUTE STROKE TREATMENT IN LARGE NIHSS PATIENTS Justin Nolte, MD Assistant Profession Marshall University School of Medicine History of Presenting Illness 64 yo wf with PMHx of COPD, HTN, HLP who was in
More informationManaging the Measures: A Serious Look at Key Abstraction Concepts for the Comprehensive Stroke (CSTK) Measure Set Session 2
Managing the Measures: A Serious Look at Key Abstraction Concepts for the Comprehensive Stroke (CSTK) Measure Set Session 2 January 28, 2015 1 to 3 PM Central Time Continuing Education Credit This course
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationDuring the first few hours of ischemic stroke, a high blood
Effects of Blood Pressure and Blood Pressure Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke Eivind
More informationAdvancing Stroke Systems of Care to Improve Outcomes Update on Target: Stroke Phase II
Advancing Stroke Systems of Care to Improve Outcomes Update on Target: Stroke Phase II Gregg C. Fonarow MD, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Lee H. Schwamm, MD UCLA Division of Cardiology; Department
More informationHERMES Time and Workflow Primary Paper. Statistical Analysis Plan
HERMES Time and Workflow Primary Paper Statistical Analysis Plan I. Study Aims This is a post-hoc analysis of the pooled HERMES dataset, with the following specific aims: A) To characterize the time period
More informationDrano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients
Drano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients Peter Panagos, MD, FACEP, FAHA Associate Professor Emergency Medicine and Neurology Washington University School
More informationComparison of Five Major Recent Endovascular Treatment Trials
Comparison of Five Major Recent Endovascular Treatment Trials Sample size 500 # sites 70 (100 planned) 316 (500 planned) 196 (833 estimated) 206 (690 planned) 16 10 22 39 4 Treatment contrasts Baseline
More informationTissue plasminogen activator (tpa) improves outcome
Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tpa in Get With The Guidelines Stroke Steven R. Messé, MD; Muhammad A. Pervez, MD; Eric E. Smith, MD, MPH; Khawaja A. Siddique,
More informationRBWH ICU Journal Club February 2018 Adam Simpson
RBWH ICU Journal Club February 2018 Adam Simpson 3 THROMBOLYSIS Reperfusion therapy has become the mainstay of therapy for ischaemic stroke. Thrombolysis is now well accepted within 4.5 hours. - Improved
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationHow to predict the affected circulation in Large Vessel Occlusive Stroke?
The ejournal of the European Society of Minimally Invasive Neurological Therapy How to predict the affected circulation in Large Vessel Occlusive Stroke? Peter Vanacker, Mohamed Faouzi, Ashraf Eskandari,
More informationThe sole effective and approved drug to treat acute ischemic
Thrombolysis in Stroke Despite Contraindications or Warnings? Benedikt Frank, MD; James C. Grotta, MD; Andrei V. Alexandrov, MD; Erich Bluhmki, PhD; Patrick Lyden, MD; Atte Meretoja, MD; Nishant K. Mishra,
More informationWAKE-UP has received funding from the European Union Seventh Framework Programme (FP7/ ) under grant agreement n
Intravenous Thrombombolysis in Stroke Patients with Unknown Time of Onset Results of the Multicentre, Randomized, Double-blind, Placebo- Controlled WAKE-UP Trial G. Thomalla, C.Z. Simonsen, F. Boutitie,
More informationThe sole effective and approved drug to treat acute ischemic
Thrombolysis in Stroke Despite Contraindications or Warnings? Benedikt Frank, MD; James C. Grotta, MD; Andrei V. Alexandrov, MD; Erich Bluhmki, PhD; Patrick Lyden, MD; Atte Meretoja, MD; Nishant K. Mishra,
More informationEndovascular Treatment for Acute Ischemic Stroke: Considerations from Recent Randomized Trials
Published online: March 13, 2015 1664 9737/15/0034 0115$39.50/0 Review Endovascular Treatment for Acute Ischemic Stroke: Considerations from Recent Randomized Trials Manabu Shirakawa a Shinichi Yoshimura
More informationThrombolytic Therapy in Clinical Practice The Norwegian Experience
Thrombolytic Therapy in Clinical Practice The Norwegian Experience Thomassen Lars Thomassen, Ulrike Waje-Andreassen, Halvor Næss ABSTRACT Background: Awaiting the European approval of thrombolysis, we
More informationCOMPREHENSIVE SUMMARY OF INSTOR REPORTS
COMPREHENSIVE SUMMARY OF INSTOR REPORTS Please note that the following chart provides a sampling of INSTOR reports to differentiate this registry s capabilities as a process improvement system. This list
More informationEFFECT OF OLDER AGE ON THE RISK OF HEMORRHAGIC COMPLICATIONS AFTER INTRAVENOUS AND/OR INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE
EFFECT OF OLDER AGE ON THE RISK OF HEMORRHAGIC COMPLICATIONS AFTER INTRAVENOUS AND/OR INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE By SVETLANA PUNDIK, M.D. Submitted in partial fulfillment of
More informationDisclosures. Anesthesia for Endovascular Treatment of Acute Ischemic Stroke. Acute Ischemic Stroke. Acute Stroke = Medical Emergency!
Disclosures Anesthesia for Endovascular Treatment of Acute Ischemic Stroke I have nothing to disclose. Chanhung Lee MD, PhD Associate Professor Anesthesia and perioperative Care Acute Ischemic Stroke 780,000
More informationMedico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke
Current Treatment Options in Cardiovascular Medicine (2011) 13:233 239 DOI 10.1007/s11936-011-0122-0 Cerebrovascular Disease and Stroke Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationProtocol for IV rtpa Treatment of Acute Ischemic Stroke
Protocol for IV rtpa Treatment of Acute Ischemic Stroke Acute stroke management is progressing very rapidly. Our team offers several options for acute stroke therapy, including endovascular therapy and
More informationSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Original Article Medical Journal of the Islamic Republic of Iran, Vol. 27, No. 3, Aug 2013, pp. 113-118 Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic
More informationClopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial
Clopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial S. Claiborne Johnston, 1 J. Donald Easton, 2 Mary Farrant, 2 William Barsan, 3 Robin A. Conwit, 4 Jordan J. Elm,
More informationBY MARILYN M. RYMER, MD
Lytics, Devices, and Advanced Imaging The evolving art and science of acute stroke intervention. BY MARILYN M. RYMER, MD In 1996, when the US Food and Drug Administration (FDA) approved the use of intravenous
More informationClinical specialist statement. Thank you for agreeing to give us a statement on your view of the technology and the way it should be used in the NHS.
Clinical specialist statement Thank you for agreeing to give us a statement on your view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationThrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register
Q J Med 2008; 1:863 869 doi:.93/qjmed/hcn2 Advance Access published on 11 August 2008 Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis
More informationSignificant Relationships
Opening Large Vessels During Acute Ischemic Stroke Significant Relationships Wade S Smith, MD, PhD Director UCSF Neurovascular Service Professor of Neurology Daryl R Gress Endowed Chair of Neurocritical
More informationJAMA. 2012;307(24):
ORIGINAL CONTRIBUTION Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator Ying Xian, MD, PhD Li Liang,
More informationRecanalization Therapy & Secondary Prophylaxis in the Elderly
Recanalization Therapy & Secondary Prophylaxis in the Elderly 21 st Annual Meeting of the Swiss Stroke Society Lausanne,11.01.2018 PD Dr. G. M. De Marchis, MD MSc Neurology & Stroke Center University Hospital
More informationTime to treatment is a critical factor in the outcome of
Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale Maarten G. Lansberg,
More informationCanadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:
More informationACUTE STROKE IMAGING
ACUTE STROKE IMAGING Mahesh V. Jayaraman M.D. Director, Inter ventional Neuroradiology Associate Professor Depar tments of Diagnostic Imaging and Neurosurger y Alper t Medical School at Brown University
More informationRural emergency department best practice for treatment of acute ischemic stroke
Rural emergency department best practice for treatment of acute ischemic stroke Aubrey J. Hoye, DO Ministry Howard Young Medical Center, Woodruff, WI Ministry Eagle River Memorial Hospital, Eagle River,
More informationStroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke
Stroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke Alexander A. Khalessi MD MS Director of Endovascular Neurosurgery Surgical Director of NeuroCritical Care University
More informationOutcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tpa for Acute Ischemic Stroke
Original Research Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tpa for Acute Ischemic Stroke Bryan Darger, BA* Nicole Gonzales, MD Rosa C. Banuelos, PhD* Hui Peng, PhD
More informationORIGINAL RESEARCH. Ischemic stroke
Ischemic stroke For numbered affiliations see end of article. Correspondence to Dr R Gupta, Emory University School of Medicine, 49 Jesse Hill Dr SE, Room 393, Atlanta, GA 30303, USA; rishi.gupta@emory.edu
More informationFunding UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
More informationTable 1. Specific changes to the FDA labeling for recombinant tissue plasminogen activator (Alteplase, Activase, Genentech, inc).
Acute Ischemic Stroke Controversies Steven R. Messé, MD, FAAN Associate professor of Neurology, Pereleman School of Medicine at the University of Pennsylvania, Philadelphia, PA Using the term controversy
More informationAnalysis of DWI ASPECTS and Recanalization Outcomes of Patients with Acute-phase Cerebral Infarction
J Med Dent Sci 2012; 59: 57-63 Original Article Analysis of DWI ASPECTS and Recanalization Outcomes of Patients with Acute-phase Cerebral Infarction Keigo Shigeta 1,2), Kikuo Ohno 1), Yoshio Takasato 2),
More informationThrombolytic therapy with intravenous tissue-type plasminogen
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome Data From Get With The Guidelines-Stroke Carolyn A. Cronin, MD, PhD; Kevin N. Sheth, MD;
More informationStroke Update Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center
Stroke Update 2015 Elaine J. Skalabrin MD Medical Director and Neurohospitalist Sacred Heart Medical Center Stroke Center Objectives 1. Review successes in systems of care approach to acute ischemic stroke
More informationParameter Optimized Treatment for Acute Ischemic Stroke
Heart & Stroke Barnett Memorial Lectureship and Visiting Professorship Parameter Optimized Treatment for Acute Ischemic Stroke December 2, 2016, Thunder Bay, Ontario Adnan I. Qureshi MD Professor of Neurology,
More informationCerebrovascular Disease lll. Acute Ischemic Stroke. Use of Intravenous Alteplace in Acute Ischemic Stroke Louis R Caplan MD
Cerebrovascular Disease lll. Acute Ischemic Stroke Use of Intravenous Alteplace in Acute Ischemic Stroke Louis R Caplan MD Thrombolysis was abandoned as a stroke treatment in the 1960s due to an unacceptable
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationClinical Features of Patients Who Come to Hospital at the Super Acute Phase of Stroke
Research Article imedpub Journals http://www.imedpub.com Clinical Features of Patients Who Come to Hospital at the Super Acute Phase of Stroke Abstract Background: The number of patients who are adopted
More informationClinical profile of patients with acute ischemic stroke receiving intravenous thrombolysis (rtpa-alteplase)
International Journal of Advances in Medicine Jagini SP et al. Int J Adv Med. 2018 Feb;5(1):164-169 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20180078
More informationReview of the TICH-2 Trial
Review of the TICH-2 Trial Mikaela Hofer, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds September 18, 2018 2018 MFMER slide-1 Objectives Review the pharmacologic options to limit hematoma expansion
More informationA common clinical dilemma. Ischaemic stroke or TIA with atrial fibrillation MRI scan with blood-sensitive imaging shows cerebral microbleeds
Cerebral microbleeds and intracranial haemorrhage risk in patients with atrial fibrillation after acute ischaemic stroke or transient ischaemic attack: multicentre observational cohort study D. Wilson,
More informationPatient characteristics. Intervention Comparison Length of followup. Outcome measures. Number of patients. Evidence level.
5.0 Rapid recognition of symptoms and diagnosis 5.1. Pre-hospital health professional checklists for the prompt recognition of symptoms of TIA and stroke Evidence Tables ASM1: What is the accuracy of a
More information